

# CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date appearing below.

6  
Washington  
8/25/88

ELI LILLY AND COMPANY

By [Signature] \_\_\_\_\_  
Signature  
Date 16 Aug 1988

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Larry W. Hertel )  
Serial No.: 07/058,219 )  
Filed : June 4, 1987 ) Group Art Unit: 123  
For : DIFLUORO ANTIVIRALS AND ) Examiner: W. Davis  
INTERMEDIATE THEREFOR )  
Docket No.: X-5707B )

## INFORMATION DISCLOSURE STATEMENT III

Commissioner of Patents and Trademarks

Washington, D.C. 20231

Sir:

Applicant submits the enclosed patent document for the assistance of the Examiner in the consideration of the present case. Applicant regrets that the document was not supplied earlier; Applicant's attorney only became aware of it after the issuance of the present action, in the course of literature study concerning a different invention.

British Patent Application 2,125,401A shows nucleosides, said to be useful against Herpes diseases, which are desoxyuridine derivatives wherein the sugar moiety may have a single fluorine atom at the 2-position. The patent's compounds are therefore obviously distinct from the present nucleosides, which must have 2,2-difluoro substitution. It is also noticeable that the British application's base moieties have a saturated alkyl substituent on the ring, which is not permissible in any of the bases used in the present compounds.

U. S. Serial No. 07/058,219 -2-

Thus, the British application is not seen to be more important than the previously-cited articles and patents which show monofluoro compounds, but it is mentioned in order to complete the record and to assure that the Examiner is fully informed.

Respectfully submitted,



Joseph A. Jones  
Attorney for Applicant  
Registration No. 26,472

Phone: 317-276-5183

Eli Lilly and Company  
Patent Division/JAJ  
Lilly Corporate Center  
Indianapolis, Indiana 46285

16 Aug 1988